Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ischemic Stroke
Biotech
Acticor halts stroke trial for blood thinner over futility
Acticor Biotech is discontinuing a phase 2/3 study of a blood thinner given alongside heart surgery based on the results of a futility analysis.
James Waldron
Jul 26, 2024 8:10am
Athersys files for bankruptcy, sells assets to Healios
Jan 9, 2024 10:38am
Athersys nears bankruptcy as cell therapy fails interim analysis
Oct 10, 2023 10:50am
MicroTransponder grabs $73M for stroke rehab neurostimulator
Sep 22, 2022 10:41am
Bayer, like its rivals, flops ph. 2 but hopes it made a splash
Aug 29, 2022 10:30am
New drug could flip the script for stroke treatment
Jul 28, 2022 11:00am
